Novel p53 inactivators with neuroprotective action: Syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives

Journal of Medicinal Chemistry

Volumn 45, Issue 23, 2002, Pages 5090-5097

  Zhu, Xiaoxiang ^a   Yu, Qian sheng ^a   Cutler, Roy G ^a   Culmsee, Carsten W ^a,b   Holloway, Harold W ^a   Lahiri, Debomoy K ^c   Mattson, Mark P ^a   Greig, Nigel H ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYPHENYL) 2 [4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOTHIAZOLYL]ETHANONE HYDROBROMIDE; 1 (3 METHOXYPHENYL) 2 [4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOTHIAZOLYL]ETHANONE HYDROBROMIDE; 1 (4 CHLOROPHENYL) 2 [4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOTHIAZOLYL]ETHANONE HYDROBROMIDE; 1 (4 FLUOROPHENYL) 2 [4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOTHIAZOLYL]ETHANONE HYDROBROMIDE; 1 (4 METHOXYPHENYL) 2 [4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOTHIAZOLYL]ETHANONE HYDROBROMIDE; 1 (4 METHYLPHENYL) 2 [4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOXAZOLYL]ETHANONE HYDROBROMIDE; 1 (4 METHYLPHENYL) 2 [4,5,6,7 TETRAHYDRO 2 IMINO 6 METHYL 3(2H) BENZOTHIAZOLYL]ETHANONE HYDROBROMIDE; 1 (4 NITROPHENYL) 2 [4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOTHIAZOLYL]ETHANONE HYDROBROMIDE; 1 (4 PHENYLPHENYL) 2 [4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOTHIAZOLYL]ETHANONE HYDROBROMIDE; 1 [4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOTHIAZOLYL] 2 BUTANONE HYDROBROMIDE; 1 [4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOXAZOLYL] 2 BUTANONE HYDROBROMIDE; 1 PHENYL 2 [4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOTHIAZOLYL]ETHANONE HYDROBROMIDE; 2 IMINO 2,3,4,5,6,7 HEXAHYDROBENZOTHIAZOLE; 2 IMINO 2,3,4,5,6,7 HEXAHYDROBENZOXAZOLE; 3 (PHENYLMETHYL) 4,5,6,7 TETRAHYDRO 2(3H) BENZOTHIAZOLIMINE HYDROBROMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; ETHYL 2 [4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOTHIAZOLYL]ACETATE HYDROBROMIDE; NEUROPROTECTIVE AGENT; PIFITHRIN ALPHA; PROTEIN INHIBITOR; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DNA DAMAGE; DRUG POTENCY; DRUG SYNTHESIS; GENE INACTIVATION; HIPPOCAMPUS; HUMAN; MOUSE; NEUROPROTECTION; NONHUMAN; SIDE EFFECT; STROKE; UPREGULATION;

ANIMALS; APOPTOSIS; BENZOXAZOLES; CAMPTOTHECIN; CULTURE TECHNIQUES; HIPPOCAMPUS; IMINES; ISCHEMIC ATTACK, TRANSIENT; NEUROPROTECTIVE AGENTS; PC12 CELLS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037038332     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020044d     Document Type: Article

References (42)

1. Mattson, M. P. Apoptosis and neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 2000, 1, 120-129.
2. Jenner, M.; Olanow, C. Understanding cell death in Parkinson's disease. Ann. Neurol. 1998, 44, S72-S84.
3. Dirnagl, U.; Iadecola, C.; Moskowitz, M. Pathobiology of ischemic stroke: An integrated view. Trends Neurosci. 1999, 22, 391-397.
4. Choi, D. W. Excitotoxic cell death. J. Neurobiol. 1992, 23, 1261-1276.
5. de la Monte, S. M.; Sohn, Y. K.; Wands, J. R. Correlates of p53-and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J. Neurol. Sci. 1997, 152, 73-83.
6. Blum, D.; Wu, Y.; Nissou, M. F.; Arnaud, S.; Benabid, A. L.; Verna, J. M. p53 and bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. Brain Res. 1997, 751, 139-142.
7. Li, Y.; Chopp, M.; Zhang, Z. G.; Zaloga, C.; Niewenhuis, L.; Gautam, S. p53-immunoreactive protein and p53 Mrna expression after transient middle cerebral artery occlusion in rats. Stroke 1994, 25, 849-855.
8. Napieralski, J. A.; Raghupathi, R.; McIntosh, T. K.; The tumor-suppressor genes, p53, is induced in injured brain regions following experimental traumatic brain injury. Mol. Brain Res. 1999, 71, 78-86.
9. Sakhi, S.; Bruce, A.; Sun, N.; Tocco, G.; Baudry, M.; Schreiber, S. S. Induction of tumor suppressor p53 and DNA fragmentation in organotypic hippocampal cultures following excitotoxin treatment. Exp. Neurol. 1997, 145, 81-88.
10. Uberti, D.; Belloni, M.; Grilli, M.; Spano, P.; Memo, M. Induction of tumour-suppressor phosphoprotein p53 in the apoptosis of cultured rat cerebellar neurones triggered by excitatory amino Acids. Eur. J. Neurosci. 1998, 10, 246-254.
11. Culmsee, C.; Zhu, X.; Yu, Q. S.; Chan, S. L.; Camandola, S.; Guo, Z.; Greig, N. H.; Mattson, M. P. A Synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid β-peptide. J. Neurochem. 2001, 77, 220-228.
12. Crumrine, R. C.; Thomas, A. L.; Morgan, P. F. Attenuation of p53 expression protects against focal ischemic damage in transgenic mice. J. Cereb. Blood Flow Metab. 1994, 14, 887-891.
13. Takimoto, C. H.; Kieffer, L. V.; Kieffer, M. E.; Arbuck, S. G.; Wright, J. DNA topoisomerase I poisons. Cancer Chemother. Biol. Response Modif. 1999, 18, 81-124.
14. Capranico, G.; Giaccone, G.; D'Incalci, M. DNA topoisomerase II poisons and inhibitors. Cancer Chemother. Biol. Response Modif. 1999, 18, 125-143.
15. Morrison, R. S.; Wenzel, H. J.; Kinoshita, Y.; Robbins, C. A.; Donehower, L. A.; Schwartzkroin, P. A. Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death. J. Neurosci. 1996, 16, 1337-1345.
16. Freeman, R. S.; Estus, S.; Johnson, E. M., Jr. Analysis of cell cycle-related gene expression in postmitotic neurons: Selective induction of cyclin D1 during programmed cell death. Neuron 1994, 12, 343-355.
17. Sadoul, R.; Quiquerez, A. L.; Martinou, I.; Fernandez, P. A.; Martinou, J. C. p53 protein in sympathetic neurons: Cytoplasmic localization and no apparent function in apoptosis. J. Neurosci. 1996, 43, 594-601.
18. Sambamurti, K.; Greig, N. H.; Lahiri, D. K. Advances in the cellular and molecular biology of the besta-amyloid protein in Alzheimer's disease. NeuroMol. Med. 2002, 1, 1-20.
19. Komarov, P. G.; Komarova, E. A.; Kondratov, R. V.; Christov-Tselkov, K.; Coon, J. S.; Chernov, M. V.; Gudkov, A. V. A Chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285, 1733-1737.
20. King, L. C.; Hlavacek, R. J. The reaction of ketones with iodine and thiourea. J. Am. Chem. Soc. 1950, 72 (2), 3722-3725.
21. Singh, A.; Mohan, J.; Pujari, H. K. Heterocyclic systems containing bridgehead nitrogen atom: Part XXV - Syntheses of imidazo[2,1-b]benzothiazoles & quinoxalino-[2,3:4′,5′]imidazo[2′, 1′-b]benzothiazoles. Ind. J. Chem. 1976, 14B, 997-998.
22. Crank, G.; Khan, H. R. Formation of Thioamide Derivatives from Reactions of Isothiocyanates with Oxazol-2-amines. Aust. J. Chem. 1985, 38, 447-458.
23. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88, 323-331.
24. Donehower, L. A.; Harvey, M.; Slagle, B. L.; McArthur, M. J.; Montgomery, C. J., Jr.; Butel, J. S.; Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992, 356, 215-212.
25. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris. p53 mutations in human cancers. Science 1991, 253, 49-53.
26. Tyner, S. D.; Venkatachalam, S.; Choi, J.; Jones, S.; Ghebranious, N.; Igelmann, H.; Lu, X.; Soron, G.; Cooper, B.; Brayton, C.; Park, S. H.; Thompson, T.; Karsenty, G.; Bradley, A.; Donehower, L. A. p53 mutant mice that display early aging-associated phenotypes. Nature 2002, 415, 45-53.
27. Clore, G. M.; Omichibski, J. G.; Sakaguchi, K.; Zambrano, N.; Sakamoto, H.; Appella, E.; Gronenborn, A. M. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 1994, 265, 334-335.
28. Lee, W.; Harvey, T. S.; Yin, Y.; Yau, P.; Litchfield, D.; Arrowsmith, C. H. Solution of the Tetrameric Minimum Transforming Domain of p53. Nat. Struct. Biol. 1994, 1, 877-890.
29. Clore, G. M.; Ernst, J.; Clubb, R.; Omichinski, J. G.; Kennedy, W. M.; Sakaguchi, K.; Apella, E.; Gronenborn, A. M. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat. Struct. Biol. 1995, 2, 321-331.
30. Jeffrey, P. D.; Gorina, S.; Pavletich, N. P. Crystal structure of the tetramerization domain of the p53 tumour suppressor at the 1.7 angstroms. Science 1995, 267, 1498-1502.
31. Wery, J. P.; Schevitz, R. W. New trends in macromolecular X-ray crystallography. Curr. Opin. Chem. Biol. 1997, 1, 365-369.
32. Miller, M.; Lubkowski, J.; Rao, J. K. M.; Danishefsky, A. T.; Omichinski, J. G.; Sakaguchi, K.; Sakamoto, H.; Appella, E.; Gronenborn, A. M.; Clore, G. M. The oligomerization domain of p53: Crystal structure of the trigonal form. FEBS Lett. 1996, 399, 166-170.
33. Zeng, X. Y.; Levine, A. J.; Lu, H. Nonp53 p53RE binding protein, a human transcription factor functionally analogous to p53. PNAS 1998, 95, 6681-6686.
34. Duan, W.; Zhu, X.; Ladenheim, B.; Yu, Q. S.; Guo, Z.; Cutler, R. G.; Cadet, J. L.; Greig, N. H.; Mattson, M. P. Synthetic p53 inhibitors preserve dopaminergic neurons and motor function in experimental parkinsonism. Ann. Neurol. 2002, in press.
35. Greig, N. H. Drug delivery to the brain by blood-brain barrier circumvention and drug modification. In The Implications of the Blood-Brain Barrier and its Manipulation; Neuwelt, E., Ed.; Plenum Press: New York, 1989; Vol. I, pp 311-367.
36. Greig, N. H. Drug Entry to the Brain and its Pharmacologic Manipulation. In Handbook of Experimental Pharmacology; Bradbury, M. W. B., Ed.; Springer-Verlag: Heidelberg, Germany, 1992; Vol. 103, pp 487-523.
37. Komarova, E. A.; Gudkov, A. V. Chemoprtection for p-53-dependent apoptosis: Potential clinical applications of the p53 inhibitors. Biochem. Pharmacol. 2001, 62, 657-667.
38. Tasaka, S.; Tanabe, H.; Sasaki, Y.; Machida, T. Synthesis of 2-phenylimidazo[2,1-b]benzothiazole derivatives as modulators of multidrug resistance for tumor cells. J. Heterocycl. Chem. 1997, 34, 1763.
39. Mekonnen, B.; Crank, G.; Craig, D. A New and facile synthesis of imidazo[2,1-b]oxazoles. J. Heterocycl. Chem. 1997, 34, 589.
40. Lahiri, D. K.; Farlow, M. R.; Sambamurti, K. The Secretion of amyloid-beta peptides is inhibited in tacrine-treated human neuroblastoma cells. Mol. Brain Res. 1998, 62, 131-140.
41. Mattson, M. P.; Cheng, B.; Culwell, A. R.; Esch, F. S.; Lieberburg, I.; Rydel, R. E. Evidence for excitoprotective and intra-neuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993, 10, 243-254.
42. Bruce, A. J.; Boling, W.; Kindy, M. S.; Peschon, J.; Kreamer, P. J.; Carpenter, M. J.; Holsberg, F. S.; Mattson, M. P. Altered neuronal and microglial responses to brain injury in mice lacking the TNF receptor. Nat. Med. 1996, 2, 788-794.